Introduction
From Harvey's anatomical studies of the heart in the 17th century to cellular and biochemical studies in the 19th century to molecular genetic studies in the late 20th century, we have moved towards understanding heart disease at increasingly granular pathophysiological levels ( Figure 1 ). In this century, microarray 1) Presented at the Second Santorini Prospective Conference ''From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment'', Santorini, Greece, Sep 30-Oct 4, 2004 *Corresponding author: C. C. Liew, Chief Scientist, Chondrogene Inc., 800 Petrolia Road, Unit 15, Toronto, Ontario, Canada M3J 3K4 Phone: q1-416-650-0060, Fax: q1-416-650-0055, E-mail: cliew@chondrogene.com gene expression portraits are helping us to understand the heart in health and in disease at the level of its expressed genome. Blood RNA-based data are now beginning to add to tissue-based microarray analyses, and blood-based gene expression profiling may come to provide an important tool for researchers to carry out investigations into system biology.
Traditional genetic expression studies that use cell lines or animal models have typically focused on one or at most a few genes and on specific molecular processes, such as cell growth and differentiation. Such studies have been invaluable in helping cardiovascular researchers to better understand the molecular basis of monogenic cardiovascular disorders, such as cardiomyopathies, arrhythmias and inherited cholesterol disorders. This research has also led to important insights into the pathophysiology of single gene disorders and of complex polygenic cardiovascular diseases (1) . The seminal work of Brown and Goldstein on familial hypercholesterolemia, for example (2) , was fundamental in establishing the link between cholesterol metabolism and atherosclerosis. Such gene-by-gene studies have left many questions unanswered. One important limitation of traditional genetic expression studies is that such studies present a portrait of disease that is essentially static. Disease, however, is a dynamic and complex process. Polygenic cardiovascular disease onset and progression, even atherosclerotic lesion regression -during therapy, for example -is driven both by (static) inherited genetic factors such as mutations or polymorphisms, and by epigenetic factors, such as cell regulatory interactions and environmental influences.
The technologies that have emerged out of the Human Genome Project have provided researchers with investigational strategies that more adequately capture the dynamic nature of disease. One such technology, the expressed sequence tag (EST) approach, emerged early in the 1990s as a promising approach to gene identification (3, 4) . In the EST approach, individual clones selected at random from a specific cDNA library are amplified and sequenced in a single pass from one or both ends of the insert, yielding a partial gene sequence known as the ''expressed sequence tag'' or EST. The ESTs are then compared against known gene sequences and existing nucleotide databases to determine whether they match to previously known genes or are as yet uncharacterized. During the 1990s laboratories began to construct cDNA libraries from cells, tissues and organs of various species and rapidly acquire EST data. Our laboratory, for example, used the EST approach to prepare an annotated compendium of approximately 25,000 distinct cardiovascular-express- Figure 1 Historical progress in cardiovascular disease research. Since the 17th century, cardiovascular disease has been diagnosed and analyzed at the anatomical level. This progressed toward the microscopic level, looking at the cellular makeup of the heart and tissues. The discovery of proteins and biochemical processes led cardiovascular research into a new area. The age of molecular biology initiated investigation into specific genes and the variations within the genes themselves. We are now in the age of genomics, which can be viewed as a high-throughput holistic extension of molecular biology, allowing for simultaneous analysis of the genes and genetic variation at the level of the complete genome. This has facilitated progress toward offering a prospective diagnosis and prognosis of cardiovascular disease, moving beyond the restriction of a retrospective diagnosis.
ed genes (4, 5) . Since 1991, more than six million human ESTs have been deposited into the dbEST division of GenBank (6) .
Compiling a database of over 111,000 cardiovascular-derived ESTs allowed us to estimate the number of genes expressed in the cardiovascular system. Using three unique approaches, including EST clustering, transcript mapping and microarray gene expression profiling, we estimated that the cardiovascular system expresses from 21,000 to 27,000 genes (5). Developing a physical map specific for the cardiovascular-expressed genome from this database for chromosomes 21 and 22 also led to the discovery of several gene clusters that demonstrated a statistically significant lower or higher physical density than would have been expected when compared against a random distribution (7). Extending the physical map to the entire genome resulted in the identification of many more cardiovascular-based gene clusters (8) .
We have also conducted a similar study on human cartilage, in which we established, from a database of ;117,000 ESTs, a transcriptome map representing between 13,000 and 16,000 unique expressed genes (9) . Our study identified a number of genomic regions that are transcriptionally ''hot'' or ''cold'' in cartilage, as well as a significant number of clusters of adjacent co-expressed genes (9) . The existence of clusters of co-expressed adjacent genes, as well as the presence of sequences in the cartilage mRNA pool encoding chromatin-remodeling proteins, is consistent with the operation of ''chromatin domain'' models of transcription in cartilage cells.
Databases of ESTs and cDNA clone libraries offer the raw materials for large-scale gene expression analysis, which since the mid-1990s has increasingly focused on cDNA microarray technology. In order to create a gene profile using microarray technology, RNA is isolated from patient tissue biopsy samples or cultured cell lines, labeled with a detectable marker and hybridized onto a microarray slide, which often contains a representative set of genes in the entire genome. Computational techniques are then used to gauge gene expression. Three types of microarray platforms predominate today: robotically spotted cDNA arrays, such as in-house custom microarray systems; spotted oligonucleotide arrays, such as the Agilent platform; and the photolithographic oligonucleotide array, such as the Affymetrix platform (10) .
Microarrays have revolutionized our approach to studying the molecular aspects of disease. The whole genome scan opens a window through which we can monitor molecular pathways of interest and determine how gene expression changes in response to various stimuli (such as drug therapy). These comparisons offer the ability to study disease as it evolves over different time points and to compare patients with different epigenetic risk factor profiles and under different environmental influences. By examining tissue biopsies or cell samples, researchers can identify a whole-genome ''portrait'' of gene expression, extract candidate genes, and conduct targeted follow-up studies that directly relate to specific cellular functions. This is a ''sieving'' approach that systematically filters the genes and pathways of interest. Such technologies allow us to view the entire genome of an organism and permit better characterization of disease as a dynamic process. Genomic analysis provides an unbiased, hypothesis-generating approach for identifying the molecular pathways of disease (11). 
Genomic profiles of heart failure
Heart failure (HF) is a syndrome with various causes, including hypertension, ischemia, congenital heart disease, cardiomyopathy and myocarditis ( Figure 2 ). The complexity of HF makes the study of its underlying mechanisms a challenge (12) . Thus, it is an excellent disease candidate for microarray investigations.
Genomic studies have proved invaluable for identifying candidates involved in HF and to corroborate the results of earlier studies. For example, Friddle et al. (13) used microarray technology in a mouse model to identify gene expression patterns altered during induction and regression of cardiac hypertrophy induced by administration of angiotensin II and isoproterenol. In this study the group was able to demonstrate that a set of known and novel genes was involved in cardiac remodeling during hypertrophy regression and that these genes were distinct from those expressed during induction of hypertrophy. Similarly, Yang et al. (14) , in the first human microarray study of end-stage HF, examined and compared gene expression in end-stage HF due to ischemic or dilated cardiomyopathy. This group identified SLIM1, a cytoskeletal protein, and gelsolin, a calcium-regulating molecule, as potentially important in human HF. In 2001, our laboratory employed the first custom-made cardiovascular-based cDNA microarray, ''CardioChip'', to identify the involvement of structural and structural-related genes such as a-actin, tropomyosin, desmin, thymosin, transgelin and g-filamen in HF (15) .
Another such study contrasting failing and non-failing human hearts demonstrated that end-stage HF is associated with an increase in matrix/cytoskeletal and proteolysis/stress proteins (16) . This same study also reported differential gene expression profiles between alcoholic, dilated and familial cardiomyopathies, with signal transduction genes being expressed at a lower level in the latter two states, possibly indicating that alcoholic cardiomyopathy does not involve neurohormonal or cytokine pathways. Boheler and colleagues (17) conducted a similar study with a larger sample size and confirmed the role of mitogen-activated protein kinase (MAPK) kinases in HF, but also found that HF profiles differed considerably among patients of different age and gender, illustrating the importance of careful sample selection. Another such ''portrait'' differentiated failing from non-failing heart tissue, but was not able to distinguish clearly between end-stage dilated cardiomyopathy (DCM) and ischemic cardiomyopathy, possibly because the late disease stage had obviated initial differences (18) .
These studies enable us to view HF in a wider context. Rather than focusing on a small number of genes or pathways in isolation, genomic studies enable researchers to monitor gene activities relative to all other genes and pathways expressed in the body. This allows us to assess whether different pathways act in tandem; it also enables us to identify important genes that at first glance may not seem relevant to the cardiovascular system. Moreover, microarray gene profiling can track changes in global gene expression during the development and progression of HF. This allows for an efficient screening of the entire genome, which is especially effective if subsequently combined with targeted techniques such as real-time RT-PCR or the use of transgenic mouse models. In recent years this strategy has been applied to a wide variety of human diseases such as cancer (19) .
Microarray portraits can also be used to infer or predict backwards from the molecular signatures to HF etiology. To address this, we compared CardioChip molecular signatures for DCM and hypertrophic cardiomyopathy (HCM), two cardiovascular diseases that result in HF via different remodeling and molecular mechanisms (20) . DCM is characterized by a dilated and hypo-contractile left and/or right ventricle (21) . It can result from a number of factors, including viral infection, coronary heart disease, hypertension or various toxic insults to the heart muscle, or it can be idiopathic. HCM is an inherited genetic defect that results in left-ventricle hypertrophy and hyper-contractility (22, 23) . In HCM, diastolic function is often abnormal despite high left-ventricular ejection fraction. Patients are at risk of sudden death, even in the absence of cardiac decompensation. Overt HF is uncommon until the patient develops atrial fibrillation or myocardial systolic dysfunction.
These two types of cardiomyopathy displayed strikingly different gene expression patterns (20) . Interestingly, HCM was characterized by upregulation of sarcomeric and ribosomal proteins, and downregulation of cell signaling/cell structure genes, including elastin and calmodulin. DCM presented the profile of a cytoskeletalopathy, showing an increase in genes related to cell defense, such as calnexin and myoglobin, and a decrease in genes encoding gene expression and metabolism proteins, such as the ring zinc finger protein and thyroid receptor interactor.
The CardioChip was also used to compare DCM and chronic Chagas' cardiomyopathy (CCC) a late-onset, aggressive cardiomyopathy that occurs years after infection with the protozoan parasite Trypanosoma cruzi, which causes Chagas' disease, common in Central and South America. In this study, we documented that these conditions also have very different gene expression profiles -over 75% of the genes differentially expressed in CCC are not expressed in dilated cardiomyopathy -and include many genes involved in inflammation (12) .
As these studies show, the molecular portraits of DCM, HCM and CCC are markedly different, although the diseases have similar clinical features and presentation of end-stage HF necessitating heart transplantation (12) . The molecular signatures of the diseases also confirm their pathophysiological mechanisms, verifying that each of the diseases leads to end-stage HF via distinct pathways. DCM may be considered a ''cytoskeletalopathy'', as it is primarily characterized by defects in cytoskeletal pathways. By contrast, HCM may be thought of as a ''sarcomyopathy'' involving differential expression of sarcomeric-related genes. CCC, for its part, might be considered a ''cytokinopathy'', primarily involving alterations in cytokines, chemokines and cell defense genes, with the IFN-g pathway playing a central role. Its molecular signature may reflect its etiology as a parasite-induced disorder.
A further analysis of DCM was conducted recently; this study utilized myocardial biopsy samples obtained from clinically stable patients with moderate HF and a 30,000q-element microarray to assess gene expression at various stages of the disease (24) . In concordance with previous studies, this study showed that over the course of the disease, DCM involved differential expression of cytoskeleton-related genes. This study also provided insights into the complex processes associated with the progression from compensated to decompensated HF, as some patients showed both a compensated expression profile (with activation of genes involved in energy production and enhanced assembly of the contractile apparatus) and decompensated HF as reflected by a ''deteriorated'' profile (involving upregulation of apoptotic and defense-response genes, and downregulation of cell cycle control genes). Such a study indicates the possibility of developing clinically useful diagnostic tests defining different stages of human HF.
Microarray analysis has also been used to characterize the genetic changes associated with cardiac fibrosis, and indicated that brain natriuretic peptide (BNP) serves as an antifibrotic factor (25) . Additional functional genomic studies have focused on cardiac hypertrophy (16), cardiac aging (26), myocardial infarction (27) and many other cardiovascular conditions that potentially lead to HF.
These studies indicate ways in which microarray analysis has been used to verify the broad outlines of specific diseases (e.g., the activity of cytoskeletal and calcium-related genes) while also identifying specific candidates for further study. Genome-wide screening thus represents a technology of considerable power: (a) to reveal clusters of genes related to health, growth, and differentiation in disease development and processes; (b) to reveal the biological pathways and networks of communication at the cellular and organ levels; (c) as a high-throughput funnel, or sieve, to identify genes associated with disease; and (d) to provide evidence for the etiology of diseases as shown in their different gene expression patterns.
The future of molecular profiling: from tissuebased to blood-based
Microarray studies of HF have mainly utilized RNA derived from tissue biopsies or heart transplant samples. The need to use tissue samples has several disadvantages. For one, samples are often difficult to obtain, especially in cardiovascular diseases such as HF where samples can sometimes only be obtained at the time of heart transplant. Gene profiling based on such tissue samples can represent only end-stage disease, as samples from early-stage heart disease are very difficult to obtain.
To exploit more thoroughly the potential of molecular signatures to analyze disease at various stages, a new and less invasive approach to obtaining samples is necessary. Blood tests are relatively non-invasive tests that have long been invaluable tools in laboratory medicine, and researchers are beginning to explore the potential of blood as a molecular or genomic diagnostic tool.
Blood has a number of characteristics that suggest it may act as a useful complement to tissue biopsy samples. First of all, blood is a highly complex fluid connective tissue that circulates throughout the body, providing physiological connectivity between tissues. Blood functions to transport nutrients, oxygen and biomolecules to cells of the body and remove cellular wastes, as well as to deliver immune cells to sites of infection and injury. As blood circulates through the body, it invariably interacts and communicates with every cell, tissue and organ as it seeks to detect cellular alterations and to restore homeostasis (Figure 3) . Second, blood is a highly dynamic tissue; blood cells turn over at a rate of approximately 1 trillion per day, which includes 200 billion red blood cells and 70 billion neutrophilic leukocytes (28) . As a result of these characteristics, the extensive set of genes expressed Figure 3 In addition to its immunological and homeostatic functions, circulating blood acts as a transport system, carrying oxygen, nutrients and hormones to, and removing waste and bioproducts from each cell within the body. Thus, the blood interacts with the tissues and organs of the body, including the microenvironment of each cell, and will respond to perturbations resulting from disease or the environment. We hypothesize that blood may give early warning of the onset of disease, and that these signals are reflected in the gene expression of blood cells. To identify the disease signatures, RNA extracted from the circulating blood cells is used to assay the levels of gene expression through microarray profiling.
in circulating blood cells also depends on the interaction and communication among cells in order to monitor and sustain homeostatic balance (29) . This also suggests that the blood is an excellent surrogate model for investigation into the biology of an entire system.
We hypothesize that bioinformation regarding the current state of health or disease of an individual is conveyed in the blood by virtue of the dynamic interactions between circulating blood cells and the cells, tissues and organs of the entire body. In view of the dynamic and interactive properties of circulating blood, blood cells may act as bioinformational scouts, indicating the presence of disease anywhere in the body (29) .
According to this hypothesis, circulating blood represents a rich resource of molecular biological information to be harvested and utilized. Environmental, physiological or disease perturbations in the body may leave a molecular signature that is detectable by analyzing blood-derived RNA. Thus, RNA from circulating blood should provide evidence of, for example, abnormal protein production, waste products, temperature-related changes, or alterations in cellular mechanisms such as apoptosis. Since blood samples can be obtained readily and with little discomfort to patients, biomarkers derived from blood RNA provide an alternative to tissue biopsy and imaging for the diagnosis and prognosis of disease.
The hypothesis has been tested in a number of recent studies, both in our laboratory and by other groups. In our recent microarray analysis, tissue-specific cardiac genes in circulating blood successfully discriminated between coronary artery disease patients and control subjects (30) . The utility of this approach has been confirmed by several studies in other laboratories showing that gene expression profiles in blood indeed reflect bodily states and disorders. Alterations in blood cell transcriptomes have been found in an increasing range of diseases, disorders and injuries, including juvenile arthritis (31), hypertension (32) (33) (34) , colorectal cancer (35) , chronic fatigue syndrome (36) , neuronal injuries (37, 38) , and trauma/burn injuries (39) .
In one example of this type of research, Morello et al. (40) compared genomic profiles of RNA derived from immortalized lymphoblast cell lines obtained from lymphocytes of patients with familial combined hyperlipidemia (FCHL) as well as control patients. The group identified 166 genes that were differentially expressed in FCHL cell lines compared to controls, and transcripts related to metabolism were enriched.
Figure 4
Gene expression profiles of lymphocytes distinguish patients with familial combined hyperlipidemia. Gene expression profiling of immortalized lymphocytes from 12 subjects with familial combined hyperlipidemia (FHCL) were compared with those from 12 subjects with normal lipid levels. A filtered set of 500 differentially expressed genes was able to separate the samples into two groups in CardioChip analysis (15) : the control group with low lipid levels and the FHCL group with high lipid levels. Thus, the static genetic component of FHCL was maintained in the cell lines and was clearly reflected in the gene expression profile. The asterisk denotes an outlier sample. Further information can be obtained from the work by Morello et al. (40) , who carried out this analysis using the alternative microarray Affymetrix chip.
In particular, early growth response 1 (EGR-1) was upregulated in patient samples. EGR-1 is a gene directly implicated in lipid metabolism and has previously been found to be upregulated in the adipose tissue of FCHL patients (41) . Downregulated transcripts included lysophospholipase 3 (LYPLA2), a lysophospholipase related to lecithin cholesterol acyltransferase, a key enzyme in plasma cholesterol esterification and in reverse cholesterol transport of high-density lipoprotein. Several additional genes differentially expressed in FCHL cells include a cluster of potential EGR-1 transcripts. These results support the hypothesis that minor, but disease-specific modifications of gene expression can be detected in blood cells (Figure 4) . The study suggests that immortalized lymphoblast cell lines retain the genetically based gene expression pattern of FCHL, and that clusters of differentially expressed genes may represent meaningful subgroups of FCHL.
We have recently reported a pilot study (42) in which we compared blood RNA from patients diagnosed with schizophrenia or bipolar disorder and healthy control subjects. In this microarray analysis we observed that both diseases exhibited a unique expressed genome molecular signature, allowing us to discriminate among the schizophrenia, bipolar disorder and control groups. We also validated changes in several potential biomarker genes for schizophrenia and bipolar disorder by RT-PCR, including some which were found to code to chromosomal loci previously linked to schizophrenia. A classification model produced from linear combinations of eight putative biomarker genes was able to discriminate between schizophrenia, bipolar disorder, and control samples, with an overall accuracy of 95-97% as indicated by receiver operating characteristic (ROC) curve analysis. It is also interesting that despite the insulation of the central nervous system by the blood-brain barrier we could still derive genomic profiles relative to cell-cell interaction and communication.
As these studies suggest, blood-derived RNA may represent a novel alternative to tissue biopsies as a source material for mRNA expression measurements. Little is known about the mechanisms by which nonblood diseases such as schizophrenia and coronary artery disease leave their mark on blood RNA such that the disease is detectable in gene profiling. However, the characteristics of blood as a dynamic, interacting, plastic tissue that acts to communicate with all of the cells of the body to maintain homeostasis suggest that it is not implausible that blood cells should retain some mark of disease perturbations in the body.
If the above premise is correct, then it may be possible to design blood-based RNA expression assays that are diagnostic for particular disease conditions. For such assays, sensitivity and specificity requirements will require consideration. For example, a set of biomarkers would require sufficient sensitivity to detect positive cases of the disease above the background of ambient gene expression in blood. Sufficient specificity would also be required, so that the absence of disease in a patient would not be contraindicated by ambient gene expression levels in the blood. Although the technical challenges may be severe, the preliminary results cited above (from the areas of schizophrenia) suggest that this may be possible to achieve.
Conclusion
HF is an excellent candidate for genomic studies, as it is a complex disease with many causes, etiologies and risk factors (both environmental and genetic). The traditional approach, that is, the study of a small number of genes or a single risk factor, would likely provide a limited and partial picture. The genomic approach, which identifies broad sets of genes and pathways expressed in different cell types, is a more efficient alternative that will expedite the understanding of this complex disease. Although still an emerging technology, microarray studies have already contributed useful molecular genetic ''signatures'', of various types of end-stage HF, such as alcoholic or ischemic and polygenic HF (DCM, HCM, CCC). In the future, we expect that clear portraits of different types of HF will emerge. Such portraits will have implications for differential diagnosis and estimation of the prognosis of each type of HF; they will also lead to the identification of new drug targets and the ability to predict drug responses by phenotype.
Using circulating blood-cell-derived RNA as opposed to tissue biopsy samples may have significant long-term implications for genomic research. Blood-cell-derived RNA obtained in a minimally invasive way allows researchers to better understand the biology systems of human disease as disease develops. Furthermore, blood-cell-derived RNA allows larger sample sizes, better patient matching (thus avoiding problems of statistical interpretation and confounding factors that weaken interpretation) and more standardized technical procedures, thus representing a convenient, rigorous, high-throughput method of gene profiling.
